On May 26, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported its partipation in the following investor conferences in the month of June (Press release, ERYtech Pharma, MAY 26, 2021, View Source [SID1234580699]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference – June 1- 4, 2021

Gil Beyen, Chief Executive Officer, will be participating in a fireside chat followed by a virtual Q&A session on Friday June 4th at 10am (ET).

WEBCAST LINK

A replay of the session will be on the Jefferies conference website, as well as on ERYTECH’s website, under the "Investors" section at investors.erytech.com, for 30-days following the conference. For more information please visit the Conferences & Events section of the Jefferies website.

JMP Securities Life Sciences Conference – June 16 & 17, 2021

Gil Beyen, Chief Executive Officer, will present a company overview followed by a virtual Q&A session on Wednesday June 16th at 2pm (ET).

WEBCAST LINK

A link to the live audio webcast as well as the replay of the webcast will be available on ERYTECH’s website, under the "Investors" section at investors.erytech.com. For more information about the JMP Securities Life Sciences Conference, please refer to the JMP conference website

Spring European Midcap Event – June 24 & 25, 2021

Gil Beyen, Chief Executive Officer and Eric Soyer Chief Financial Offier will participate in one-on-one meetings on Thursday June 24th.

For more information about the Spring European Midcap Event, please refer to the CF&B conference website

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

On May 26, 2021 Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30 p.m. ET (Press release, Celldex Therapeutics, MAY 26, 2021, View Source [SID1234580698]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 30 days following the event.

On May 26, 2021 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET (Press release, Merus, MAY 26, 2021, View Source [SID1234580697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of the presentation will be available on the Investors page of the Company’s website. An archived presentation will be available on the Merus website for a limited time.

On May 26, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, reported the grant of a new patent (number ZL201480073584.3) entitled "Combined Preparations for the Treatment of Cancer" by the Chinese Patent Office (Press release, Immutep, MAY 26, 2021, View Source [SID1234580677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Chinese patent follows the grant of the corresponding European, Australian, Japanese and United States patents, as announced separately throughout 2019 and 2020. The new patent protects Immutep’s intellectual property relating to combination therapy comprising (a) lead active immunotherapy candidate eftilagimod alpha (efti or IMP321), which is a LAG-3 fusion protein (LAG-3Ig), and (b) a chemotherapy agent. The chemotherapy agent is oxaliplatin, carboplatin, or topotecan, and the patent provides protection in the territory of mainland China.

The new patent is owned by Immutep S.A.S. and exclusively licensed to Immutep’s partner in China, EOC Pharma ("EOC"). The patent expiry date is 19 December 2034.

Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer, noted: "Oxaliplatin, carboplatin and topotecan continue to be commonly used forms of chemotherapy in China and more broadly. Furthermore, combinations of chemotherapy and active immunotherapies have begun to be approved for the treatment of advanced solid tumors in recent years. As such, this new patent provides protection in the important Chinese territory for a range of novel and highly relevant chemo-immunotherapies featuring efti that could be developed in the future by our partner, EOC Pharma."

EOC Pharma CEO, Xiaoming Zou, said: "We are very pleased that our partner, Immutep, continues to make important progress in building a robust patent estate around efti. This underpins our continued investment in this unique and promising candidate, and provides a range of future development options for our business."

About efti in China

Efti is exclusively licensed to EOC for the territory of Greater China (namely mainland China, Hong Kong S.A.R, Macao S.A.R. and Taiwan). Under its agreement with Immutep, EOC will make further milestone payments to the Company if efti achieves specific development milestones, as well as pay sales-based royalties.

On May 26, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET (Press release, ORIC Pharmaceuticals, MAY 26, 2021, View Source [SID1234580663]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.